Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests" and similar expressions are intended to identify forward-looking statements. These statements are based on Phio Pharmaceuticals Corp.'s (the "Company")

current beliefs and expectations. Such statements include, but are not limited to, statements about the impact to our business and operations by the recent coronavirus outbreak, the future development of the Company's products (including timing of clinical trials and related matters associated therewith), the expected timing of certain developmental milestones, expectations and assumptions regarding the results of our preclinical studies, potential partnership opportunities, the Company's competition and market opportunity and pro forma estimates. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to risks and uncertainties in the Company's business, including those identified under "Risk Factors" in the Company's most recently filed Annual Report on Form

10-K and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur

after the date of this presentation.

Mission Statement

Develop innovative cancer treatments that overcome tumor immunosuppression and weaponize the immune system against cancer without genetic modificationMaximize the value of our self-delivering RNAi technology for immuno- oncology

1. Develop adoptive cell therapy (ACT) products with increased anti-tumor effectiveness, and partner with leading providers

2.

Develop RNAi drugs targeting immuno-suppression in the tumor micro-environment (TME)

INTASYL™

Technology

(self-delivering RNAi)

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Phio Pharmaceuticals Corp. published this content on 09 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 March 2021 12:04:02 UTC.